LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Authors: Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman‐Censits, Gopa Iyer, Christof Vulsteke, S.H. Park, Sang Joon Shin, D.E. Castellano Gauna, Giuseppe Fornarini, J-R. Li, M. Gumus, Nataliya Mar, S. Narayanan, Xin Yu, Seema Rao Gorla, B.M.S. Homet Moreno van der Heijden - Annals of Oncology 2023 cited by 135